Funding Statement This research received no external funding
While tirzepatide is a gold-standard diabetes treatment right now, retatrutides multi-pathway profile suggests it could offer an equally powerful, if not uniquely specialized, alternative for severe insulin resistance and advanced metabolic syndrome once approved
Approval, if it comes, is likely still at least 1218 months away, depending on the pace of remaining readouts and regulatory review
People ages 65 and older who are overweight meaning they have BMIs between 27and 30 generally will not qualify for the lower-cost GLP-1 drugs through the Bridge program
When does appetite suppression actually start on retatrutide Appetite suppression is usually the first noticeable effect, and it is often what people mean when they ask whether retatrutide is "working." The timeline for this specific effect varies, but the published data provides useful benchmarks
Many patients who stop taking it tend to gain back weight or lose the health benefits they had achieved